Accession ID: MIRT004955 [miRNA, hsa-let-7b ::
PDGFRA, target gene]
| pre-miRNA ID | hsa-let-7b LinkOut: [miRBase ] |
|---|---|
| Synonyms | LET7B, MIRNLET7B, hsa-let-7b, let-7b, MIRLET7B |
| Description | Homo sapiens let-7b stem-loop |
| 2nd Structure of pre-miRNA |  |
| Mature miRNA | hsa-let-7b-3p |
|---|---|
| Mature Sequence | 60| CUAUACAACCUACUGCCUUCCC |81 |
| Evidence | Experimental |
| Experiments | Cloned |
| Putative hsa-let-7b-3p Targets | LinkOut: [ TargetScanS 5.1 | MicroCosm | microRNA.org | miRecords | miRDB | miRo | miRNAMap 2.0 ] |
| Mature miRNA | hsa-let-7b-5p |
| Mature Sequence | 6| UGAGGUAGUAGGUUGUGUGGUU |27 |
| Evidence | Experimental |
| Experiments | Cloned |
| Putative hsa-let-7b-5p Targets | LinkOut: [ TargetScanS 5.1 | MicroCosm | microRNA.org | miRecords | miRDB | miRo | miRNAMap 2.0 ] |
 |
| Gene Symbol | PDGFRA LinkOut: [ Entrez Gene | BioGPS | Wikipedia | iHop ] | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | CD140A, MGC74795, PDGFR2, RHEPDGFRA | ||||||||||||||||||||
| Description | platelet-derived growth factor receptor, alpha polypeptide | ||||||||||||||||||||
| Transcript | NM_006206 LinkOut: [ RefSeq ] | ||||||||||||||||||||
| Expression | LinkOut: [ BioGPS ] | ||||||||||||||||||||
| KEGG Pathway |
hsa04010 MAPK signaling pathway - Homo sapiens (human) hsa04020 Calcium signaling pathway - Homo sapiens (human) hsa04060 Cytokine-cytokine receptor interaction - Homo sapiens (human) hsa04144 Endocytosis - Homo sapiens (human) hsa04510 Focal adhesion - Homo sapiens (human) hsa04540 Gap junction - Homo sapiens (human) hsa04810 Regulation of actin cytoskeleton - Homo sapiens (human) hsa05200 Pathways in cancer - Homo sapiens (human) hsa05214 Glioma - Homo sapiens (human) hsa05215 Prostate cancer - Homo sapiens (human) hsa05218 Melanoma - Homo sapiens (human) |
||||||||||||||||||||
| Putative miRNA Targets on PDGFRA | LinkOut: [ TargetScan 5.1 | MicroCosm | miRNAMap 2.0 ] | ||||||||||||||||||||
| 3'UTR of PDGFRA (miRNA target sites are highlighted) |
>PDGFRA|NM_006206|3'UTR 1 TAACTGGCGGATTCGAGGGGTTCCTTCCACTTCTGGGGCCACCTCTGGATCCCGTTCAGAAAACCACTTTATTGCAATGC 81 AGAGGTTGAGAGGAGGACTTGGTTGATGTTTAAAGAGAAGTTCCCAGCCAAGGGCCTCGGGGAGCGTTCTAAATATGAAT 161 GAATGGGATATTTTGAAATGAACTTTGTCAGTGTTGCCTCTTGCAATGCCTCAGTAGCATCTCAGTGGTGTGTGAAGTTT 241 GGAGATAGATGGATAAGGGAATAATAGGCCACAGAAGGTGAACTTTGTGCTTCAAGGACATTGGTGAGAGTCCAACAGAC 321 ACAATTTATACTGCGACAGAACTTCAGCATTGTAATTATGTAAATAACTCTAACCAAGGCTGTGTTTAGATTGTATTAAC 401 TATCTTCTTTGGACTTCTGAAGAGACCACTCAATCCATCCATGTACTTCCCTCTTGAAACCTGATGTCAGCTGCTGTTGA 481 ACTTTTTAAAGAAGTGCATGAAAAACCATTTTTGAACCTTAAAAGGTACTGGTACTATAGCATTTTGCTATCTTTTTTAG 561 TGTTAAAGAGATAAAGAATAATAATTAACCAACCTTGTTTAATAGATTTGGGTCATTTAGAAGCCTGACAACTCATTTTC 641 ATATTGTAATCTATGTTTATAATACTACTACTGTTATCAGTAATGCTAAATGTGTAATAATGTAACATGATTTCCCTCCA 721 GAGAAAGCACAATTTAAAACAATCCTTACTAAGTAGGTGATGAGTTTGACAGTTTTTGACATTTATATTAAATAACATGT 801 TTCTCTATAAAGTATGGTAATAGCTTTAGTGAATTAAATTTAGTTGAGCATAGAGAACAAAGTAAAAGTAGTGTTGTCCA 881 GGAAGTCAGAATTTTTAACTGTACTGAATAGGTTCCCCAATCCATCGTATTAAAAAACAATTAACTGCCCTCTGAAATAA 961 TGGGATTAGAAACAAACAAAACTCTTAAGTCCTAAAAGTTCTCAATGTAGAGGCATAAACCTGTGCTGAACATAACTTCT 1041 CATGTATATTACCCAATGGAAAATATAATGATCAGCAAAAAGACTGGATTTGCAGAAGTTTTTTTTTTTTTTTTCTTCAT 1121 GCCTGATGAAAGCTTTGGCGACCCCAATATATGTATTTTTTGAATCTATGAACCTGAAAAGGGTCAGAAGGATGCCCAGA 1201 CATCAGCCTCCTTCTTTCACCCCTTACCCCAAAGAGAAAGAGTTTGAAACTCGAGACCATAAAGATATTCTTTAGTGGAG 1281 GCTGGATGTGCATTAGCCTGGATCCTCAGTTCTCAAATGTGTGTGGCAGCCAGGATGACTAGATCCTGGGTTTCCATCCT 1361 TGAGATTCTGAAGTATGAAGTCTGAGGGAAACCAGAGTCTGTATTTTTCTAAACTCCCTGGCTGTTCTGATCGGCCAGTT 1441 TTCGGAAACACTGACTTAGGTTTCAGGAAGTTGCCATGGGAAACAAATAATTTGAACTTTGGAACAGGGTTGGCATTCAA 1521 CCACGCAGGAAGCCTACTATTTAAATCCTTGGCTTCAGGTTAGTGACATTTAATGCCATCTAGCTAGCAATTGCGACCTT 1601 AATTTAACTTTCCAGTCTTAGCTGAGGCTGAGAAAGCTAAAGTTTGGTTTTGACAGGTTTTCCAAAAGTAAAGATGCTAC 1681 TTCCCACTGTATGGGGGAGATTGAACTTTCCCCGTCTCCCGTCTTCTGCCTCCCACTCCATACCCCGCCAAGGAAAGGCA 1761 TGTACAAAAATTATGCAATTCAGTGTTCCAAGTCTCTGTGTAACCAGCTCAGTGTTTTGGTGGAAAAAACATTTTAAGTT 1841 TTACTGATAATTTGAGGTTAGATGGGAGGATGAATTGTCACATCTATCCACACTGTCAAACAGGTTGGTGTGGGTTCATT 1921 GGCATTCTTTGCAATACTGCTTAATTGCTGATACCATATGAATGAAACATGGGCTGTGATTACTGCAATCACTGTGCTAT 2001 CGGCAGATGATGCTTTGGAAGATGCAGAAGCAATAATAAAGTACTTGACTACCTACTGGTGTAATCTCAATGCAAGCCCC 2081 AACTTTCTTATCCAACTTTTTCATAGTAAGTGCGAAGACTGAGCCAGATTGGCCAATTAAAAACGAAAACCTGACTAGGT 2161 TCTGTAGAGCCAATTAGACTTGAAATACGTTTGTGTTTCTAGAATCACAGCTCAAGCATTCTGTTTATCGCTCACTCTCC 2241 CTTGTACAGCCTTATTTTGTTGGTGCTTTGCATTTTGATATTGCTGTGAGCCTTGCATGACATCATGAGGCCGGATGAAA 2321 CTTCTCAGTCCAGCAGTTTCCAGTCCTAACAAATGCTCCCACCTGAATTTGTATATGACTGCATTTGTGTGTGTGTGTGT 2401 GTTTTCAGCAAATTCCAGATTTGTTTCCTTTTGGCCTCCTGCAAAGTCTCCAGAAGAAAATTTGCCAATCTTTCCTACTT 2481 TCTATTTTTATGATGACAATCAAAGCCGGCCTGAGAAACACTATTTGTGACTTTTTAAACGATTAGTGATGTCCTTAAAA 2561 TGTGGTCTGCCAATCTGTACAAAATGGTCCTATTTTTGTGAAGAGGGACATAAGATAAAATGATGTTATACATCAATATG 2641 TATATATGTATTTCTATATAGACTTGGAGAATACTGCCAAAACATTTATGACAAGCTGTATCACTGCCTTCGTTTATATT 2721 TTTTTAACTGTGATAATCCCCACAGGCACATTAACTGTTGCACTTTTGAATGTCCAAAATTTATATTTTAGAAATAATAA 2801 AAAGAAAGATACTTACATGTTCCCAAAACAATGGTGTGGTGAATGTGTGAGAAAAACTAACTTGATAGGGTCTACCAATA 2881 CAAAATGTATTACGAATGCCCCTGTTCATGTTTTTGTTTTAAAACGTGTAAATGAAGATCTTTATATTTCAATAAATGAT 2961 ATATAATTTAAAGTTA Target sites Provided by authors Predicted by miRanda |
||||||||||||||||||||
| miRNA-target interactions (Predicted by miRanda) |
|
| miRNA:Target | hsa-let-7b :: PDGFRA [ Functional MTI ] |
|---|---|
| Validation Method | qRT-PCR |
| Conditions | Namalwa |
| Original Description (Extracted from the article) | ... six putative miRNAs targeting MYC mRNAs, let-7a and let-7b of the let-7 cluster were distinctly overexpressed by 1.6- and 1.73-fold, respectively.//mir-98 was increased by 2.1-fold in compoundexposed cells relative to control (Table 1). ... - Sampson, V. B. Rong, N. H. Han, J. Yang, Q. et al., 2007, Cancer Res. |
| Article |
- Sampson, V. B.
Rong, N. H.
Han, J.
Yang, Q. et al. - Cancer Res, 2007
Regulation of the MYC oncogene remains unclear. Using 10058-F4, a compound that inhibits MYC-MAX transcription factor, MYC protein and gene expression were down-regulated in Namalwa cells, a Burkitt lymphoma. Compound 10058-F4 decreased MYC mRNA (45%), MYC protein (50%), and cell growth (32%). MYC-MAX transcription factor was disrupted 24 h after treatment, resulting in transcriptional inhibition of target genes. Because microRNAs (miRNA) disrupt mRNA translation, let-7a, let-7b, and mir-98 were selected using bioinformatics for targeting MYC. Inhibition of MYC-MAX transcription factor with 10058-F4 increased levels of members of the let-7 family. In inhibited cells at 24 h, let-7a, let-7b, and mir-98 were induced 4.9-, 1.3-, and 2.4-fold, respectively, whereas mir-17-5p decreased 0.23-fold. These results were duplicated using microRNA multianalyte suspension array technology. Regulation of MYC mRNA by let-7a was confirmed by transfections with pre-let-7a. Overexpression of let-7a (190%) decreased Myc mRNA (70%) and protein (75%). Down-regulation of Myc protein and mRNA using siRNA MYC also elevated let-7a miRNA and decreased Myc gene expression. Inverse coordinate regulation of let-7a and mir-17-5p versus Myc mRNA by 10058-F4, pre-let-7a, or siRNA MYC suggested that both miRNAs are Myc-regulated. This supports previous results in lung and colon cancer where decreased levels of the let-7 family resulted in increased tumorigenicity. Here, pre-let-7a transfections led to down-regulation of expression of MYC and its target genes and antiproliferation in lymphoma cells. These findings with let-7a add to the complexity of MYC regulation and suggest that dysregulation of these miRNAs participates in the genesis and maintenance of the lymphoma phenotype in Burkitt lymphoma cells and other MYC-dysregulated cancers.
LinkOut: [PMID: 17942906]
|